SQZ Biotechnologies Company
- Jurisdiction
United States - ISIN
US78472W1045 (SQZ )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
2
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
5
/ 7
Profile
SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Read full profile
Stock price
Fundamentals
- Net revenue
€10.46M - Gross margin
100.0% - EBIT
-€62.80M - EBIT margin
-600.1% - Net income
-€2.91M - Net margin
-27.9%
Statement period: - (published )
Dividends
No dividend payouts